Expression of PSMA on Prostate Tumor Cells: Potential Utility for Phenotypic Precision Medicine

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer.1-3

PSMA is expressed in >80% of men with prostate cancer.1,4-6

High PSMA expression is correlated with poor outcomes.5,7,8

PSMA is expressed in certain nonprostate tissues, such as the kidneys, small intestine and salivary glands, at levels lower than in the prostate.9-11

 

PSMA may offer an opportunity for a phenotypic precision medicine approach in prostate cancer.12-14

PSMA is a transmembrane protein that is anchored in the cell membrane of prostate cancer epithelial cells. The binding of PSMA-targeted radioligands to PSMA may enable a phenotypic precision medicine approach, which is the ability to select patients based on a phenotypic biomarker, visualized using diagnostic imaging. This has the potential to be followed by investigational radioligand therapy, which targets the same phenotypic biomarker on prostate cancer cells.1,15,16

 

 

PSMA Expression Video

PSMA Expression Video

 

CT, computed tomography; Ga, gallium; MOA, mechanism of action; PET, positron emission tomography.

References: 1. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Cancer. 1998;82(11):2256-2261; 2. Kinoshita Y, Kuratsukuri K, Landas S, et al. World J Surg. 2006;30(4):628-636; 3. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Urol Oncol. 1995;1(1):18-28; 4. Hope TA, Aggarwal R, Chee B, et al. J Nucl Med. 2017;58(12):1956-1961; 5. Hupe MC, Philippi C, Roth D, et al. Front Oncol. 2018;8:623; 6. Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. J Nucl Med. 2020;61(3):405-411; 7. Marchal C, Redondo M, Padilla M, et al. Histol Histopathol. 2004;19(3):715-718; 8. Ross JS, Sheehan CE, Fisher HA, et al. Clin Cancer Res. 2003;9(17):6357-6362; 9. O’Keefe DS, Bacich DJ, Heston WD. Prostate. 2004;58(2):200-210; 10. Troyer JK, Beckett ML, Wright GL Jr. Int J Cancer. 1995;62(5):552-558; 11. Sokolo RL, Norton KC, Gasior CL, et al. Prostate. 2000;43(2):150-157; 12. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ. Prostate. 2009;69(10):1101-1108; 13. Hofman MS, Lawrentschuk N, Francis RJ. Lancet. 2020;395(10231):1208-1216; 14. Maurer T, Gschwent JE, Rauscher I, et al. J Urol. 2016;195(5):1436-1443; 15. Israeli RS, Powell CT, Fair WR, Heston WD. Cancer Res. 1993;53(2):227-230; 16. Silver DA, Pellicer I, Fair WR, Cordon-Cardo C. Clin Cancer Res. 1997;3(1):81-85.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.